Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension.

ABSTRACT:

Background

To improve clinical outcome, patients with inoperable and residual chronic thromboembolic pulmonary hypertension (CTEPH) can be treated with riociguat. The aim of this study is to explore long-term outcomes and to compare our 'real world' data with previous research.

Methods

We included all consecutive patients with technical inoperable and residual CTEPH, in whom riociguat therapy was initiated from January 2014 onwards, with patients followed till January 2019. Survival, clinical worsening (CW), functional class (FC), N-terminal pro brain natriuretic peptide (NT-proBNP) and 6-minute walking distance (6MWD) were described yearly after riociguat initiation.

Results

Thirty-six patients (50% female, mean age 64.9 ± 12.1 years, 54% WHO FC III/IV and 6MWD 337 ±

SUBMITTER: van Thor MCJ 

PROVIDER: S-EPMC6396196 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature